GTHX - Earnings call transcript Q2 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day. Thank you for standing by, and welcome to the G1 Therapeutics Second Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions]. to conference like host, to now Mr. would turn over the your I Roberts. Will sir. Please go ahead,

William Roberts

for Thank session launch second adult afternoon, platinum/etoposide-containing quarter cell Sarah. that and on call the in and the you, prior was Drug Good regimen our when patients update. these to of GX to to business issued discuss conference small or website, and including with a financial the of Food results our approved and February call, the regimen this update can afternoon on the COSELA March incidence business will after this XX, XXXX, question-and-answer On administered on press second The early which of topotecan-containing or found in progress XXXX. XXXX in became XXXX, was extensive-stage Administration decrease ES-SCLC a results News will GXtherapeutics.com. A U.S. follow provide channel quarter section in closed available be by everyone, of an cancer myelosuppression the lung the period financial overview release remarks. to and the our prepared market welcome in of corporate chemotherapy-induced team

statements. Such materially risks may you results implied actual from represent begin, I and of XXXX. that want Reform management's differ today's these Before today meaning we forward-looking uncertainties in judgment of involve to that statements those within Litigation or could contains of to Act the remind as by statements webcast the and Securities expressed cause Private

X, Commission, or are the please corporate represent refer Any on Securities forward-looking views today, available and from For more and our to uncertainties, August SEC of information filings as on our our statements XXXX. website. the risks with which Exchange such

over the our With Financial the our I'll on turn Medical are Officer; and Officer. Chief today Jack. Executive that, Chief Jack? Raj to Officer; me Jen Chief call Bailey, call Jack our Moses, Malik, Joining

John Bailey

from quarter you the afternoon, one it to clinical second our execution, it a COSELA the our of as programs. of joining Will. Good early readout as Today's us thank on everyone, relates on commercial and of is and our launch both Thanks, to relates focus for headline call today. ongoing continued

focused we our toward this continued made we the drug. availability long-term groundwork equally goal with myeloprotection Now It because the believe of This the ensuring chemotherapy small cancer drive can with with treating or to the regimens. cancer COSELA our help COSELA long-term to away of to first is We COSELA's of commitment impacts drug. and It with patients people during of to we move on we the to been shared lung treating effects protection of And at I lung altogether significant mission to the access next after therapy. cancer to them from joined as the cell treating But as cell prevent paradigm-changing quarter, is patients small the only GX, help has damage people proactive offer value our commercial these broad proactive side different we as when lives and for progress single GX side a confident GX myelosuppression oncologists am is by shareholders. many drugs remain of also improve second against I done, multilineage core tangible cancer. of enabling for use team lay impacted important a in decrease as and indications. occurrence seek therapy dangerous the the allows effects instead, myelosuppressive individually certain to

non-small X Phase cell X trial lung During breast in patients the the with in metastatic triple-negative COSELA, pivotal cancer in the cancer. initiated cancer trials second initiated which trial dosing clinical a for including bladder registrational colorectal addition new was and in quarter, This and is we in first with to trials II quarter.

X trials II second starting with the readouts So registrational in in ongoing total, X XXXX. III now we half Phase of multiple trials Phase have and

to expect then on have to the will I a of trial full that further uptake and we of of will the introduced upcoming immune-based initiate quarter second COSELA fourth our access we on for of of and of define of and also commercial action the the last quarter. Raj quarter efforts Now lot will leading lagging provide that COSELA. and anti-tumor efforts important our of provide on to cover an on content today. during medical the XXXX, COSELA indicators cover some first we this sales, update second call. an the the clinical mechanism milestones in quarter touch update He designed also year the

I'll will Then quarter. financial Finally, Jen provide back for the be concluding the comments. results some for

on that forward. COSELA Soma Now announced her the wish her for and before our that reasons. certainly for and we organization quarter, best and the left to Monday, you professional We the appreciate the discuss of Gupta launch contributions likely personal planning we saw the results going

including business our and specialties, August and him management. I on tremendous all strategy, execution, success of oncology, co-promotion proven Healthcare history starts at also that venture a look commercial areas new majority-owned in and and performance hired really including strategist North GlaxoSmithKline. experience you consistent across we America, Chief driving forward announced He same have of having a a former XX, and Perry, next update. President, with Andrew Marketing meet Andrew Commercial time commercial leader is commercial U.S. on We variety at by a Vice especially the a Officer; launch to the ViiV joint has of wide

our The of Now launch million the a Boehringer to during in the us turning and coming gain net in first and inclusion efforts ending booking key systems the last update. commercial resulted for remain attention sales commercial months on the X well. GX quarter the hospital various to combined of quarter to June And sets. XX. COSELA team for Ingelheim as Much order of with community formulary focus spent and months the this will was practices $X.X

key process On of these requiring that with practicer and you of they cover. of order inclusion, country, and the we a P&T a formulary have institution, in doctor into the familiar update. follow meetings lagging those For engagement, last this seen slow affect I'll a and quarter-over-quarter, exist can reimbursement, our sets. having where It's worth leading successful then I primarily year, X call, multistep awareness, noting incorporation now it's of coverage and open scheduled advocacy and in focus indicators out the utilization. to to EHR a taken, of number decision which variety not due progress the planned postponed, which will P&T speed set our areas: help on we

Now are for and unaided both aided solid. awareness,

on the awareness of of XX%, questions based an our this upon both prompts in at was benchmark As launch. with oncology unaided was are this without specific and product above June, awareness These in indication at aided point end COSELA awareness or of familiarity for COSELA XX%.

Most for place are made X within positive months And the of seeing written coverage regarding is been we pending patient B, all Part have and in other we of availability. the payer terms Now coverage coverage. the label. commercial when formal reimbursement, of forms is government and in have XX% any Medicare of XX% XX% or now have provide first approximately payers on-label filed of coverage to product is of policies remaining importantly, top pushback and of payers lives. U.S. covering claims. XX% decisions X reimbursement not that X Approximately the COSELA

proceeded with We still have for have some had how their top approval formulary into XX are order of organizations inclusion order top COSELA incorporate into XX determining COSELA sets. to all of our Not XXX our organizations use their at set. XXX of P&T process and have a and

the We expect additional approvals months. over coming

J for you and may C received in and as our recently we permanent filed both. recall, Code March, Now Code we a

or Our across tool add-on stated all provides also C payment effective saw The to were COSELA. technology for we payment on XXXX. through DRG as our new of the Code It above for hospitals channels and a issued sites provider And for care NTAP, that X. October become for morning, effective just effective all this became hospital will July outpatient system use X, J amount. pass you permanent additional Code October NTAP important payment, an billing on become will is X

to engagement perspective. on Moving

pharmacists June, many institutions QX, team achieved additional who nearly we post-COVID such know will calls of the remain nurses XX% of while stakeholders of the environment. functions reach care in X,XXX improve yet approximately virtual targeted to has At in-person And as almost end enabling the our made believe and of space. and time, critical in ratio of or we virtual. support of how quickly how still are were don't end XX% to other calls prescription to calls X,XXX virtual the over As an HCPs a the will these targeted

As are given not hospital top accounts March. date coming some oncology had the point, have the XXX number any of the accounts. or do depth be efforts COSELA issue, at across macro perspective, demand head using recently that these XX our in many community the increasing to quarter, end to academic hospitals. also across those peer from way we category stated, expected continued closely of community the areas, from so. to into again, is reach were our from We most at however, monitoring drive therapeutic up this our as increasingly in orders capabilities priority only audience. are utilization are the organizations of These At the approaching breadth end remaining depth is also lagging and X XX organizations, our to unique second of virtual from our but as other be of will a which of oncology levels. of with our From priority from next we underscores driving the ordered to clinics correct, maturation others vital which of the This COSELA from to or in essential XX% This breadth pre-COVID will and of of adoption we a companies of practice March. are encouraging and XX important few this organizations, the continue U.S., the the trial physicians directionally into or hospitals many target is received drug months. that XX% up an came

are close, channel in want on some the Now before I in quarter. third comment things to I we the seeing

which seen have orders, in believe recent some is We addressable. softness we

than the As of the slower second heard are solid you've despite a opening ideal the just performance quarter country. metrics for

is accounts shows that We that product clinically trial the The have physician drug drug as excellent, encouraging embracing with and good experience data the have it. performing is expected, awareness. are we

can be depth strong So achieved.

the is depth Our I breadth, driving said, directionally challenge. as is next but correct,

country others We have the are this on underperforming. some of dimension, regions however, are that outperforming

and to will We all stronger look address country execution this consistent and regions. across drive in the more

our second product summarize, aided awareness baseline both the net over for just this. to million, quarter were $X.X are So for a and above sales unaided like

have operational We through several hurdles. moved

many guidelines having to For still payer example, P&T while the processes and yet NCCN reviews complete.

coverage effective this on October received seen no have we NTAP We Code, J C latter permanent and in X and our of have reimbursement, being with Code, year. the and issues X

to We sales offices. possible buy-and-bill community selling evolve impact variance also into even and practices forward. intend their as a of improve for important going is their opening willingness systems virtual in-person target and while will sale we will And environment and monitor COSELA, likely receive to like continue virtual continue hospital of to the our and effective the capabilities more remain on to in a critical COVID-XX as and our reps

an clinical and I'll update Now on it Raj? second our the with Raj quarter. efforts medical that, for over turn during to

Rajesh Malik

topics. good Thanks, afternoon, Jack, cover X going and to everyone. I'm

the overview First, on an of brief to of then end year quarter, we I'll the the we medical initiated II in of From medical a which study I the data It's we important before few and designed second among identifying dialogue. of to COSELA. ensuring on quarter, amount scientific of of avenues efforts intend will mechanism introduce trials to medical I'll for tremendous X action a communications medical data. expect one define affairs initiate our of execute to includes and that of second perspective, we Phase generate that quarter. community during during further a a small a the broad new the our provide plan continue the this affairs visibility a update our provide trial

presented meeting quarter, or the of patients we ISPOR, estimated X ISPOR live virtual small for during example, posters with a and lung economic meetings, and presence cell Research, Outcomes myelosuppression data extensive-stage presented For the cancer. including Pharmacoeconomics describing and International impact At and had we ASCO. Society treating among at the

model of the in via our our a in the posters, using advances extensive-stage our booth, Our estimating peer cell in chemotherapy cause extensive-stage that favorable for from poster was at meeting program virtual prior particular interest with incidence when cancer. indicates small provided U.S. were give of innovation cell model, the addressing sponsoring cost to with commercial ASCO, cancer during very a key that treatment based estimated costs value COSELA opinion projected COSELA The called is adverse lung economically myelosuppressive also optimism We approximately economic the patients in cost-benefit view small use. an $XX,XXX and savings payer perspective. per is leaders reduction events total on long-awaited and their in oncology lung lung small on-label CME projected with patient treatment presenting active Overall, associated a cell cancer. interacting myelosuppression

I we've interest our approval our studies year. real-world generation. platform as start call, study scientific of program the We've investigator-initiated some the of marked will mentioned evidence and and in on this had later Finally, the since last interest in these been in pleased COSELA,

working assess can so to Additionally, practice. burden of the they oncology own that trial with their chemotherapy-induced myelosuppression we are clinical centers Switching progress. in now

the the and double-blind, trial Phase trials is on second multicenter, with cell prior II lung X we and for Our randomized, lung the X, second May, have inhibitor I'll most ongoing, of XXX placebo-controlled during COSELA who a cancer Phase breast non-small accounting diagnoses States. is docetaxel United colorectal discuss so Phase In last third-line metastatic We common and initiated chemotherapy. the call, the study administered cancer we the new cancer discussed X today. III lung treated cancer Preserve been in of cell XXX,XXX patients a our approximately lung to in type of setting initiated the XX% previously checkpoint IIs trial triple-negative cancer Non-small in nearly with quarter.

of For X-year in despite the patients survival and ultimately of progress inhibitors, of the treatment chemotherapy. unfortunately, primary cancer, during rate the people X%. lung use immunotherapy with to after on is majority or survival of therapy compared overall effect diagnosed COSELA PD-X or The cell And the placebo. trial the evaluate with non-small disease, metastatic only is endpoint to for metastatic including PD-LX improvements

myeloprotection compared our other anti-tumor benefit COSELA in to will evaluate and placebo efficacy will endpoints Secondary assess as and the also trials multi-lineage of safety.

in see We expect to interim XXXX. data the first half of

overall past The There COSELA June, maintenance or study for they XX to plus of other advanced to And gemcitabine/platinum Patients new a receive X%, treatment with is in evaluate we the open-label avelumab X will cases PRESERVE during initiated chemotherapy will secondary maintenance bladder inhibitor, X, bladder In assigned arms. study. or in arm, arm, platinum-based evaluate patients urothelial of endpoint other II Next, checkpoint chemotherapy, carcinoma. X COSELA prior Phase that followed with metastatic under overall antitumor therapy In the in therapy. X:X avelumab every locally administered years. the measures rate XX cancer unfortunately, has approximately by randomly primary progression-free maintenance of as one COSELA by they improved metastatic the efficacy. approximately are first-line not followed year. chemotherapy cancer survival is survival Key to the are therapy. endpoints bladder X-year being randomized number XX,XXX untreated avelumab of and a immune

and of multilineage COSELA the evaluate chemotherapy-induced myeloprotective also myelosuppression safety. will on effects We

see half We XXXX. expect to second the of data in

we tumor along In will announce the in designed triple-negative variety regulatory maximize COSELA. of COSELA. believe in tumor to do mechanism following to by The of trials conduct cancer, we in looking happy Finally, function of action. mechanism ratio of we'll be microenvironment of trial that. with further of anti-tumor as is with changes upcoming II that we action this the that immune-based in T I'm clinic, believe a will after patients ensure is the must exactly continually Phase we treatment value we we what that in evaluate COSELA CDX to to COSELA assessing an COSELA with the develop believe trial broadly T administration the applicable cells the other immune changes assessments clinical a microenvironment, of of cells at study to breast define help early-stage

more time. design expect trial announce later at will detail we trial on provide to and year, We initiation that of the this this

Before comment sections in are I submit more FDA the to to to in Fast frequent review briefly with us cancer. Designation with on drugs ongoing clinical with quarter we NDA discuss eligible of the submission, a breast the plan, an I'll the chemotherapy recent a for completed priority This Designation approval program. Jen for COSELA basis. turn I'll important combination for forward on development FDA Track rolling allowing NDA With engagements rolling and this Fast the is to triple-negative and our XXXX. of Jen? to closely advance conclude, as look results with pathways, that, potential of the for Track review We over second pivotal through call FDA as financial COSELA working

Jennifer Moses

and Raj, everyone. afternoon, Thanks, good

financial quarter will second our our in of points release disclosures. focus available few for As key the I results XXXX are and press mentioned, on Will XX-Q. full from a Today,

of quarter million. Our million, and $X.X net revenue $X.X XXXX million total of of revenue comprised revenue was second the for $X.X of license product

of PHS variability organization. mid-teens in in expect to realized gross is percentage of main forward. in a teens adjustment a driver mid- our the to For gross-to-net gross net sales our revenue, product to to high realize net percentage we percentage net and The to the going

milestone with payment related this from and We revenue benefit the of license cancer. to a Our was third-line and SImcere development initiation small specifically second related cell of Simcere, our study variety in million of from agreement in license the bridging a to primarily ways. first-line trilaciclib $X lung extensive-stage partnership

the Of royalties, June participating ability TNBC help only of these to but participate believe on burn X benefits course, trial enroll $X.X have but this to additional future months this million. at pace. in studies, sold and not ended will clinical their sites and help and control both appropriate Cost current which as we studies, CRC an provide was trials. includes we milestones also also discussed us our for continue in such is our to cash financial XX, XXXX, goods Simcere

the continue of XXXX. active of GX's As primarily increase COSELA a associated to costs to spend, of quarter to $XX.X as for prelaunch periods. of decrease majority will and external the ingredients R&D of reminder, and in is to impact the in million the additional future trials costs cost a clinical an preclinical due in initial to as a second These and pharmaceutical in research is until to were million development. which R&D increase in with prior related were second compared decrease to discovery by and the FDA clinical manufactured expenses and $XX.X XXXX presentation manufacturing drug support as therefore, prior trial expense were well product sales offset depleted sold inventory manufacturing is for costs related The costs was incurred quarter recorded periods expense previously in sold. development and goods the inventory expenses approval of

closing the equivalents spend to to increases quarter fund quarter the we the quarter $XX.X compensation in technology, administrative ended financial second expenses was over of expect expense XXXX back into for headcount services to With were turn activities information cash and be increase and an million, other costs. commercialization increase second administrative We for and largely second and million of the to in XXXX. Our with comments. $XXX our million Jack? The current position on Jack to and XXXX. to cash professional operations increase SG&A selling, for in $XX.X due that, due of some compared I'll in general increased and call sufficient

John Bailey

well. Thank Raj you, as Jen,

living with the close cancer always, for want we inspiration. thank I call, to, as their before the Now people

of only important Lung cancer, of staff specifically people Cancer we're know, a I'd lung past, acknowledge World the oncology present, we and oncologists, care As who and living experienced have to work the the their like couple impact for nurses, that Day, with those past thoracic due and it. days to families

the are myeloprotection this for multilineage work the GX of importance doing and that we well aware of proactive for cancer only patients and are a is at with there need drug. We lung great first

before the to widely forward focused today. on Q&A, me in is executing just we heavily over heard tried getting team you've let combined term. steps commercial took Now second adopted what the The the plan COSELA and recap and early quarter move long

We issues have no with reimbursement.

hold to trials virtually. impact adapt COVID registrational our X do in over to ensure and We we up, target effectively We as III as X are to U.S. new II to will barriers. them trials cell initiated non-small stay time, quarter, a cancer open Phase lung continues organization triple-negative monitor second metastatic the breast the patients bladder Phase trial that with and to the in cancer. that we of our possible. virtual, continue in we as expect reaching calls We change continue but the majority will however, of where sales instances In

a of of anti-tumor year COSELA. further to to Phase initiate mechanism new expect also late We define II this trial action the

thank COSELA you to result, time afternoon. received the And a us cash regulatory triple-negative numerous earlier guidance, patient a by for providing to unchanged our give is the other I half we for finally, pathway guidance to runway last into Track We've is second breast next this from our cancer, your taking support set As new XXXX. and of in Fast of drugs benefits. expect starting Designation data in readouts which recently used important have regulatory year.

slate before November this again speak many turn in that, Hopefully, our person of With conferences call of I'm remind time in of summer though non-deal during the we'll would Q&A. to you roadshows. and sure and due see will please fall many you and I'll ask in over it format listeners virtual the close to call, as on we We then question. can late Operator, a how the you well. see healthcare

Operator

Instructions]. [Operator

Your first question Chad Needham from from line Company. comes Messer the of &

Chad Messer

maybe on congrats of being little bit was wondering lot quarter this but a in importance if that can J put maybe Obviously, this educate talk uptake. there the morning, point factor more recently there's naivety, that you a could own reimbursement met. major on launch, some an given? to of perspective -- to NTAP further also is see early any maximum on that. actual in getting And importance decision the as that can about that's I'm it's reimbursed pretty are about a the codes, is a well my you if say you This granted? solid And milestones you sort at amount in or was us reported a as of amount if which

John Bailey

what C I Code, Chad. view Code, all would it NTAP, as the questions. very reimbursement the at to, J you Thanks, positive frankly, the environment. the and look Appreciate both mean, When we speaks Yes. a

of those, are course, All CMS. via of

market, which, policies. several COSELA every written allowing according we had to flow is the payer also We mentioned, have label, and as claims to through formal for commercial

whether I've X.X and launch it a a in My probably for normally think concerns what a of seen your We in feel product good. reimbursement. says I very, product, new point, very this decades it's good is experience commercial personal one it all or patients. So as or Medicare the to decade coverage as is speaks biggest is certainly

terms that it's NTAP of specific in of will a those the for Now itself, minority more in be the inpatient patients started setting. --

the patients very when of J research. upon market COSELA Code a couple entire But basically, in is the and waterfront the that you Code, you've with percentage small got that our So based C covered.

and So in it's coverage why really helpful. look I'm when an you But sharing totality, it the really environment. reimbursement at just the extremely it's that's It's NTAP. positive

Chad Messer

Very helpful and again. congrats

Operator

And line comes & of your the from Company. next question Joseph from Cowen Thome

Joseph Thome

would be areas or better outperforming on are maybe Are agents others sites? care we're space other TNBC. pair helpful. sort maybe sites sort that looking was one, underperforming. at to Maybe on or using I additional to Trodelvy supportive was then and development more maybe on last might the approved geography, an agents like it Will is ADC? specific trial with any some And COSELA expanding based you know be of maybe are reasonable the information clinical just some first the upcoming Obviously, that kind study. some reasons of then indicated that that year, step forward? in it why be there COSELA Any of approved to of happening, be seem was

John Bailey

one, side, It first I'll more on the it's handle small then This -- I'll over Sure. boundaries geographic and no it really there's flip -- on is when execution cancer. second it to one. Raj the certainly, the Joe. to comes lung cell

on issues partner this know execution. aligned our the are. that. We We're is is what with then really at things, -- So

Some of it requires training.

the is more line across bottom it's country. we making to are attention. solvable, sure of it the Some we solve and forward that is, working But

turn TNBC that of study, potential to the terms In let me Raj. Boston,

Rajesh Malik

COSELA mechanism. to very data define a Yes. TNBC ratio. the that MOA are about There's study, Tregs the effect of particular, lot of Joe, on on CDX-to-Treg on yes, we so further excited in

So about will be And that we focus. that we'll initiation our study. more talk as of near the

clearly including yes, TNBC. that's a exploring in Regarding since entrenched definitely spaces, of as is a class in that study of ADC, this drugs well becoming number we're interested

Operator

line BTIG. your question from And next comes from Shrader Tom of the

Thomas Shrader

drug. easy a Congratulations. Not launch time an to

as know? third you second clinical lung cell Just questions for line, announced. myelopreservation is cancer, have a to first sense your approval do do? trials well? many couple no to to just sense about trials get how there line show to What trials you you're line think your had on an non-small So the you would Or you you I is way how have going many of in to if run

John Bailey

fair Tom. -- think going for you folks a a COSELA build vision I and types. It's so answer up one -- proof we I tumor Yes. of think on across continue that this going to have have execute different don't of and We these appreciate great a figure we're And now. it. have to question, for lot to and beyond of a to to tumor-agnostic repository we really try an array regimens studies tried we're

they'll So a to point, I give a tough to it's broader payers whether compendia the or label, say at choose in is the to and would regulators begin different some not What a perspective listings, lot predict. reimburse. of it take

after label. So X formal to the reimbursement have with change pan the separate a I broader of label so think we regulatory many sort versus getting studies

but we're to on continue to COSELA Track these we Designation Fast going we're we bodies broader with So sure regulatory can the can And execute market to now indications. things where engage get make with continue for again, the across these. the -- to like encouraged

Thomas Shrader

Great. And urothelial question trial. on second the a

COSELA enough the you're Or there maintenance CDKX/X avelumab So here? during use. to Or maintaining on only? there? just COSELA going COSELA What's a extending is have is? thought active the Is on efficacy

Rajesh Malik

Yes. Tom, this is Raj.

will if So not has of X not design then up avelumab gem/platinum. sorry was patients disease actually to if The as And my receive I progressed, the get clear is they in cycles remarks. maintenance.

well as We're give control platinum So avelumab as arm. COSELA that with to is going gemcitabine maintenance. the

well in that data of have we combining inhibitor, suggests checkpoints. duration it preclinically treatment checkpoint of alone good mechanism data a So as it's There's COSELA. chemo throughout of all with terms for as combination both a action the in our and and with of actually there's rationale

the for design. that's the rationale So

Operator

next question from from David comes the of your And Securities. Wedbush Nierengarten line

David Nierengarten

a the bit payment. more detail on NTAP little could, I if Maybe

bladder survival, second there reimbursement static broader the place where support getting a relative Tom's other at expand see be does a of point, types relative you'll in you benefit don't where for scenario there mean, I if look a the question obviously, myelosuppression in mechanism that And watching necessarily study. agents? at on you there Neulasta to approval a Is the the accelerate a to myelopreservation least there. endpoint or white tumor or progression-free for Specifically, or to multiple is other physicians' then you'll maybe cancer Are plan process to a cell -- a on on study myelopreservation?

John Bailey

Raj the more economics the have cost on intent I the to using really very inpatient avoids where, a it bit bladder. favorable it's you from recovery mean, or speak NTAP, the when payment in, first from and a DRG first the especially the the to NTAP net whole an where more penalize at cetera. avoid if and years take Yes, on ago again, of improve setting potential the is patient the the you in the little if administration NTAP that system comes for fee, I'll I'll and outcomes, was innovation The NTAP, got look whether healthcare COSELA. applicable are all, for may one and et economics, Yes, setting on then look not new set even there's it it of one started

a whether takeaway. provide economics our to it continues I here, it's from to just We've have issue broader and is setting. patients. in really would for patients the key scenario So frankly, standpoint, really -- with inpatient COSELA go those got, the commercial say or back those with I again, for favorable optimal But would Medicare that reimbursement just coverage

let have -- that. the to speak bladder, terms So of Raj me in but

Rajesh Malik

so this Yes, is, David. comments make. X I'd

study. first open-label is this The is an

So a obviously, signal, that we would the certainly strong data. think I myelo be a possibility. there is is And if looking at

myelo relatively is XX in XX small The is it's to of this and patients, per patients, our when date, numbers experience second arm. is apparent there that a signal, in

well. this of actually could to So up size be sufficient pick study that as

David Nierengarten

on bladder in what it's of of that the the myelosuppression Yes, part is rate patients. kind was background

to assume or a you patients? fewer in see I with short sufficient a it's then, order mentioned, as So delta

Rajesh Malik

Yes.

this both carbo. cisplatin, gemcitabine, both and is -- it So includes really

myelosuppressive. preferred, the ineligible, get both in And cis cis obviously So they're we carbo. but

get reasonable on read I to think patients of a it's a So that. number yes,

Operator

And Butler comes your Tony line question Roth from next [Operator the Instructions]. from of Castle.

Tony Butler

on, bladder only Just wondered two PRESERVE to speak and noticed there questions, there's PRESERVE And enrolling or Raj patients, if NSCLC, PRESERVE activity clinical X PRESERVE respect that really I in I X enrolling sites. ongoing. also that trials clinical with trials, in the currently a start X X. X has they're and and seems are cancer certainly tremendous which It on side are to of amount would you one in in going that. then and

but appreciate trials having can I on enrollment. the I they're company, -- I ongoing wanted just small for know your and and realize a cumbersome new, I be So thoughts X site

Rajesh Malik

Tony.

initiated other -- May, June. in the in both the So one studies one yes, no, we're

that's And is more couple process. in there to activation a of So the the visible them actually point for we're very study. of are that be much on continuous days are currently site always a part the updated other sites that takes and clinicaltrials.gov. It

enrolled in to cancer the the We've we and are same patients patients on cell but expect enrolled. non-small soon. bladder lung yes, study, being happen So

Operator

like this would Jack further showing back I'm turn no the go sir. Please conference I now to Mr. time. ahead, Bailey. question at to

John Bailey

operator. Thank you,

maximize We of lung these future are unique of to clinical bringing with and trials actively this cell cancer in drug small cancers. conducting intelligently COSELA the variety applicability and value to designed extensive-stage a patients

us As a Thank forward. always, for today. updated good as we to I you look keeping forward you Have afternoon. move joining

Operator

and for concludes a this conference have your today's And Thank all call. participation, day. you wonderful

all You may disconnect.

G1 Therapeutics (GTHX) 5 Aug 212021 Q2 Earnings call transcript